Loading…
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $67M | $-276M | $-279M | $-71M | -160.0% | 25.2% | - |
| 2024 | $54M | $-169M | $-174M | $134M | -42.1% | - | - |
| 2023 | $0M | $-150M | $-153M | $-125M | -38.4% | - | - |
| 2022 | $0M | $-135M | $-136M | $-111M | -32.3% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 53.88 | 67.48 |
| Cost Of Revenue | 0 | 0 | 0 | 0.06 |
| Gross Profit | 0 | 0 | 53.88 | 67.42 |
| Operating Expense | 139.87 | 165.80 | 247.08 | 371.06 |
| Operating Income | -139.87 | -165.80 | -193.19 | -303.63 |
| EBITDA | -134.85 | -150.23 | -169.50 | -275.82 |
| EBIT | -135.61 | -151.08 | -170.35 | -276.86 |
| Pretax Income | -135.84 | -152.63 | -171.97 | -278.37 |
| Tax Provision | 0 | 0 | 2.02 | 0.30 |
| Net Income | -135.84 | -152.63 | -173.98 | -278.67 |
| Net Income Common Stockholders | -135.84 | -152.63 | -173.98 | -278.67 |
| Total Expenses | 139.87 | 165.80 | 247.08 | 371.11 |
| Interest Expense | 0.23 | 1.55 | 1.62 | 1.51 |
| Interest Income | 4.25 | 14.72 | 22.85 | 26.77 |
| Research And Development | 92.81 | 115.23 | 169.97 | 251.07 |
| Selling General And Administration | 47.05 | 50.57 | 77.11 | 119.98 |
| Normalized EBITDA | -134.85 | -150.23 | -169.50 | -275.82 |
| Normalized Income | -135.84 | -152.63 | -173.98 | -278.67 |
| Basic EPS | -2.03 | -2.08 | -2.02 | -3.18 |
| Diluted EPS | -2.03 | -2.08 | -2.02 | -3.18 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0.21 | 0.21 |
| Net Income From Continuing Operation Net Minority Interest | -135.84 | -152.63 | -173.98 | -278.67 |
| Reconciled Depreciation | 0.76 | 0.85 | 0.85 | 1.03 |
| Reconciled Cost Of Revenue | 0 | 0 | 0 | 0.06 |
| Net Interest Income | 4.03 | 13.17 | 21.23 | 25.26 |
| Net Income From Continuing And Discontinued Operation | -135.84 | -152.63 | -173.98 | -278.67 |
| Total Operating Income As Reported | 0 | -165.80 | -193.19 | -303.63 |
| Diluted Average Shares | 66.99 | 73.23 | 86.16 | 87.68 |
| Basic Average Shares | 66.99 | 73.23 | 86.16 | 87.68 |
| Diluted NI Availto Com Stockholders | -135.84 | -152.63 | -173.98 | -278.67 |
| Net Income Including Noncontrolling Interests | -135.84 | -152.63 | -173.98 | -278.67 |
| Net Income Continuous Operations | -135.84 | -152.63 | -173.98 | -278.67 |
| Net Non Operating Interest Income Expense | 4.03 | 13.17 | 21.23 | 25.26 |
| Interest Expense Non Operating | 0.23 | 1.55 | 1.62 | 1.51 |
| Interest Income Non Operating | 4.25 | 14.72 | 22.85 | 26.77 |
| General And Administrative Expense | 47.05 | 50.57 | 77.11 | 119.98 |
| Other Gand A | 47.05 | 50.57 | 77.11 | 119.98 |
| Operating Revenue | 0 | 0 | 53.88 | 67.48 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Kura Oncology, Inc.this co. | KURA | - | - | - | -160.0% | - |
| Actuate Therapeutics, Inc. Common stock | ACTU | $68M | - | 8.45 | -280.5% | - |
| LENSAR, Inc. | LNSR | $65M | - | -2.48 | 131.7% | -3.17 |
| Pulmonx Corporation | LUNG | $51M | - | 0.92 | -99.8% | -0.71 |
| Accuray Incorporated | ARAY | $50M | - |
| 0.94 |
| -2.0% |
| -107.66 |
| INmune Bio Inc. | INMB | $35M | - | 1.50 | -195.3% | -0.38 |
| Myomo, Inc. | MYO | $31M | - | 2.68 | -136.6% | -2.33 |
| Tvardi Therapeutics, Inc. | TVRD | $29M | - | 1.37 | -87.0% | 0.07 |
| Tevogen Bio Holdings Inc. | TVGN | $27M | - | -1.52 | 319.1% | -1.64 |
| Peer Median | - | - | 1.15 | -93.4% | -1.64 | |